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Available online 24 April 2012The Japanese Catheter Ablation Registry (JCAR) is a survey of
catheter ablation for a variety of arrhythmias. It was planned and
carried out by the Japanese Heart Rhythm Society (JHRS)—afﬁ-
liated committee of catheter ablation. The aim of this registry is to
collect data in order to manage the performance and safety of
catheter ablation of arrhythmias in Japan.
This is the second report on JCAR focusing on subjects
who underwent catheter ablation for the treatment of atrial
ﬁbrillation (AF).
Details of the registry were previously reported. In brief, data
of the procedures for catheter ablation, results, complications, and
clinical proﬁles of patients who underwent ablation for any form
of arrhythmia from January 2008 to July 2010 were anonymously
collected.
Until the end of 2010, 88EP centers listed in the Appendix
voluntarily submitted data on 967129 sessions. The total num-
ber of session was 8469. The number of arrhythmias treated
was 8545. Among these, 2291 cases of AF ablation were included
(27.1%).
The numbers of patients with paroxysmal AF, persistent
AF, and long-lasting persistent AF were 1519, 468, and 304,76/$ - see front matter & 2012 Japanese Heart Rhythm Society. Published by E
x.doi.org/10.1016/j.joa.2012.02.014
esponding author. Tel.: þ81 44 844 3546.
ail address: murakawa@med.teikyo-u.ac.jp (Y. Murakawa).respectively. Table 1 shows clinical proﬁles of the patients.
Long-lasting persistent AF was associated with longer-term mor-
bidity and decreased left ventricular function. The prevalence of
nonischemic cardiomyopathy was greater in those with persistent
or long-lasting persistent AF.
Pharmacological treatments and their clinical outcome are
summarized in Table 2. Subjects with long-lasting persistent AF
took fewer antiarrhythmic agents than those with paroxysmal or
persistent AF. However, bepridil was more widely used in
patients with long-lasting AF.
Table 3 compares the prevalence of risk factors for throm-
boembolism among the 3 types of AF. There was noticeable inter-
group variation in the proportion of older patients, history of
congestive heart failure, and hypertension.
Techniques for pulmonary (PV) isolation and other ablation
sites are shown in Table 4. Instruments, RF settings, and AF
provocation after the treatment are also given. Because the irriga-
tion catheter system was not approved until July 2009, irrigation
catheter usage is not shown. Compared with paroxysmal AF,
persistent AF and long-lasting persistent AF required ablation of
the left atrium, coronary sinus, or sites with complex fragmented
atrial electrogram (CFAE).
Pharmacological treatments at discharge are listed in Table 5.
We intend to present further observations, such as complica-
tions and recurrence of AF, in subsequent reports.lsevier B.V. All rights reserved.
Table 2
Previous pharmacological treatments and their effect.
Type of AF Paroxysmal Persistent Long-lasting persistent p value
No. 1519 468 304
No. of AA 2.271.4 Effective cases 2.271.3 Effective cases 1.771.2% Effective cases o0.001
Ia AA 904 (59.5%) 9.0% (82) 244 (52.1%) 5.8% (13) 100 (32.9%) 4.0% (4) o0.001
Ic AA 1033 (68.0%) 8.7% (90) 263 (56.2%) 7.2% (19) 122 (40.1%) 1.7% (2) o0.001
b blockade 451 (29.7%) 7.3% (33) 173 (37.0%) 6.4% (11) 98 (32.2%) 6.1% (6) o0.02
Amiodarone 51 (3.4%) 27.5% (14) 35 (7.5%) 14.3% (5) 17 (5.6%) 11.8% (2) o0.001
Sotalol 28 (1.8%) 25.0% (7) 9 (1.9%) 0% (0) 6 (2.0%) 0.0% (0) n.s.
Bepridil 382 (25.1%) 16.0% (61) 181 (38.7%) 19.3% (35) 131 (43.1%) 19.1% (25) o0.001
Others 145 (9.5%) 4.1% (6) 47 (10.0%) 6.4% (3) 38 (12.5%) 15.8% (6) n.s.
Numbers of subjects who have a history of treatment with each antiarrhythmic agent are given.
Percentages in parentheses indicate proportions of the total number of patient.
Ratios of effective treatment with each agent are presented together with actual numbers of subjects.
P values of inter-group difference in the number of AA or in the proportion of subject treated with each agent are shown.
AA: Antiarrhythmic drug.
Table 3
Risks of thromboembolism.
Type of AF Paroxysmal Persistent Long-lasting persistent p value
No. 1519 468 304
AgeZ65 yr 547 (36.0%) 181 (38.7%) 67 (22.0%) o0.001
DM 152 (10.0%) 53 (11.3%) 35 (11.5%) n.s.
History of TE 67 (4.4%) 16 (3.4%) 18 (5.9%) n.s.
History of CHF 162 (10.7%) 116 (24.8%) 69 (22.7%) o0.001
Hypertension 566 (37.3%) 200 (42.7%) 97 (31.9%) o0.01
DM: Diabetes mellitus, TE: thromboembolism, CHF: Congestive heart failure.
Table 1
Clinical proﬁle of patients.
Type of AF Paroxysmal Persistent Long-lasting persistent p value
Patient proﬁle No. 1519 468 304
Sex (male/female) 1164/355 380/88 259/45 o0.002
Age 61711 61711 58710 o0.001
Term of morbidity (year) 4.474.8 4.475.8 5.675.7 o0.001
UCG LVEF (%) 60719 55718 54722 o0.001
LAD (mm) 36712 40712 38716 o0.001
Underlying disease Valvular HD 67 (4.2%) 48 (10.3%) 13 (4.3%) o0.001
Nonischemic cardiomyopathy 73 (4.8%) 43 (9.2%) 32 (10.5%) o0.001
Thyroid disease 20 (1.3%) 4 (0.9%) 7 (2.3%) n.s.
Hypertension 544 (35.8%) 193 (41.2%) 112 (36.8%) n.s.
Congenital HD 12 (0.8%) 6 (1.3%) 1 (0.3%) n.s.
Chronic respiratory disease 9 (0.6%) 7 (1.5%) 3 (1.0%) n.s.
IHD 85 (5.6%) 25 (5.3) 10 (3.3%) n.s.
SSS 69 (4.5%) 18 (3.8%) 3 (1.0%) o0.02
None (Lone AF) 745 (49.%) 196 (41.9%) 159 (52.3%) o0.01
AA: antiarrhythmic agent, LVEF: left ventricular ejection fraction, LAD: left atrial diameter, HD: heart disease.
IHD: ischemic heart disease, SSS: sick sinus syndrome.
Table 4
Techniques and instruments used for AF ablation.
Type of AF Paroxysmal Persistent Long-lasting persistent p value
No. 1519 468 304
Ablation site
PV Individual PV 300 (19.7%) 89 (19.0%) 63 (20.7%) n.s.
Ipsi-lateral PV 1129 (74.3%) 351 (75.0%) 214 (70.4%) n.s.
Box isolation 200 (13.2%) 51 (10.9%) 52 (17.1%) o0.05
SVC SVC isolation 100 (6.6%) 29 (6.2%) 20 (6.6%) n.s.
Others Focal 60 (3.9%) 13 (2.8%) 16 (5.3%) n.s.
LA line 300 (19.7%) 156 (33.3%) 135 (44.4%) o0.001
CS 46 (3.0%) 34 (7.3%) 31 (10.2%) o0.001
CFAE 155 (1.2%) 94 (20.1%) 99 (32.6%) o0.001
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Table 4 (continued )
Type of AF Paroxysmal Persistent Long-lasting persistent p value
No. 1519 468 304
Device CARTO 874 (57.5%) 247 (52.8%) 145 (47.7%) o0.005
EnSite 66 (4.3%) 26 (5.6%) 19 (6.3%) n.s.
Ring catheter 849 (55.9%) 282 (60.3%) 183 (60.2%) n.s.
Ablation catheter 4 mm 667 (43.9%) 188 (40.2%) 109 (35.9%) o0.05
Ablation catheter 8 mm 660 (43.4%) 247 (52.8%) 153 (50.3%) o0.001
RF setting Power 32.373.8 W 32.773.8 W 32.874.1 W o0.05
Temperature 50.275.21 C 51.075.11 C 51.174.41 C o0.001
AF provocation
Not performed 477 (31.4%) 173 (37.0%) 153 (50.3%) o0.001
Performed AFZ1 min 231(15.2%) 103 (22.0%) 62 (20.4%) o0.001
AFo1 min 816 (53.7%) 192 (41.0%) 88 (28.9%) o0.001
PV: Pulmonary vein, SVC: Superior vena cava, LA: left atrium, CS: coronary sinus.
CFAE: Complex fractionated atrial electrogram, AF provocation: Outcome of post-ablation provocation of AF.
Table 5
Pharmacological treatment at discharge.
Type of AF Paroxysmal Persistent Long-lasting persistent p value
No. 1519 468 304
Class Ia AA 94 (6.2%) 27 (5.8%) 19 (6.3%) n.s.
Class Ic AA 169 (11.1%) 53 (11.3%) 39 (12.8%) n.s.
Beta blockade 202 (13.3%) 90 (19.2%) 42 (13.8%) o0.002
Amiodarone 19 (1.3%) 31 (6.6%) 8 (2.6%) o0.001
Sotalol 4 (0.3%) 4 (0.9%) 2 (0.7%) n.s.
Bepridil 178 (11.7%) 118 (25.2%) 87 (28.6%) o0.001
ACEI 32 (2.1%) 23 (4.9%) 5 (1.6%) o0.002
ARB 196 (12.9%) 66 (14.1%) 19 (6.3%) o0.005
Statin 64 (4.2%) 23 (4.9%) 7 (2.3%) n.s.
Others 86 (5.7%) 31 (6.6%) 14 (4.6%) n.s.
ACEI: Angiotensin converting enzyme inhibitor, ARB: Angiotensin II receptor blocker.
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Aichi Medical University School of Medicine (Nagakute)
Ayase Heart Hospital (Tokyo)
Bell Land General Hospital (Sakai)
Chiba-Nishi General Hospital (Matsudo)
Chikamori Hospital Heart Center (Kochi)
Edogawa Hospital (Tokyo)
Fukui Prefectural Hospital (Fukui)
Fukuoka Wajiro Hospital (Fukuoka)
Fukuyama City Hospital (Fukuyama)
Gunma University (Maebashi)
Hiratsuka Kyosai Hospital (Hiratsuka)
Hiroshima Red Cross Hospital & Atomic-bomb Survivors Hos-
pital (Hiroshima)
Hokkaido Social Insurance Hospital (Sapporo)
Hokkaido University (Sapporo)
Hirosaki University (Hirosaki)
Hyogo College of Medicine (Nishinomiya)
IMS Katsushika Heart Center (Tokyo)
Japanese Red Cross Kumamoto Hospital (Kumamoto)
Jichi Medical University (Shimotsuke)
Juntendo University Urayasu Hospital (Urayasu)
Kameda Medical Center (Kamogawa)
Kanazawa Medical University (Uchinada)
Kawachi General Hospital (Osaka)
Kawasaki Medical School (Kurashiki)
Kobe University (Kobe)
Kochi University (Kochi)
Kokura Memorial Hospital (Kitakyushu)Kouseiren Takaoka Hospital (Takaoka)
Kure Kyosai Hospital (Kure)
Kyusyu University (Fukuoka)
Maizuru Kyosai Hospital (Maizuru)
Matsue Red Cross Hospital (Matsue)
Matsue Seikyo Hospital (Matsue)
Mie University (Tsu)
Nagano Red Cross Hospital (Nagano)
Nagoya Tokushukai General Hospital (Kasugai)
National Center for Global Health and Medicine (Tokyo)
National Hospital Organization Hokkaido Medical Center
(Sapporo)
National Hospital Organization Kyusyu Medical Center
(Kitakyushu)
National Hospital Organization Okayama Medical Center
(Okayama)
Nihon University (Tokyo)
Nippon Medical School (Tokyo)
Ogikubo Hospital (Tokyo)
Ohta Nishinouchi General Hospital (Koriyama)
Oita University (Oita)
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Showa University (Tokyo)
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Tachikawa Medical Center (Nagaoka)
Tazuke Kofukai Medical Research Institute, Kitano Hospital
(Osaka)
Teikyo University School of Medicine, Mizonokuchi Hospital
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Tokai University (Isehara)
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Tokyo Medical University (Tokyo)
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Toyohashi Heart Center (Toyohashi)
Tsuchiura Kyodo General Hospital (Tsuchiura)
Tsukuba Memorial Hospital (Tsukuba)
University of Fukui (Eiheiji)
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(Kitakyushu)
Yamagata University (Yamagata)
Yamanashi Prefectural Central Hospital (Kofu)
Yokkaichi Municipal Hospital (Yokkaichi)
Yokohama General Hospital (Yokohama)
Yokohama Minami Kyosai Hospital (Yokohama)
Yokohama Rosai Hospital (Yokohama)
